Abstract
Cryptococcosis causes disseminated disease in AIDS patients. In contrast to what occurs in laboratory conditions, a large capsule is produced by Cryptococcus neoformans in vivo during infection. The aim of this study was to compare the in vitro activity of different antifungal agents against 34 clinical isolates of C. neoformans var. grubii without or with capsule induction (CLSI, CLSI-C, respectively), following the CLSI M27A3 document. Capsule induction was obtained by addition of NaHCO(3) and incubation with CO(2). The geometric means of the MICs, in µg ml(-1), for CLSI and CLSI-C cultures, respectively, were 1.9 and 9.8 for fluconazole; 0.04 and 0.08 for itraconazole; 0.04 and 0.05 for voriconazole; 0.16 and 0.38 for amphotericin B; and 1.6 and 5.6 for 5-flucytosine. Thus fluconazole showed the highest MICs after capsule induction. Determination of antifungal activity after capsule induction may be clinically relevant and could be used to evaluate the correlation between in vitro results and clinical outcome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
